Phibro Animal Health Corporation Announces Leadership Transition to Support Long-Term Growth Strategy
Phibro Animal Health Corporation a leading global animal health and nutrition company, today announced a planned leadership transition designed to support the Company’s continued growth, operational excellence, and long-term strategic objectives. Effective July 1, 2026, at the conclusion of the Company’s fiscal year, Jack Bendheim will transition from his current roles as Chairman, Chief Executive Officer, and President to assume a newly defined position as Executive Chairman. Daniel (Dani) Bendheim will succeed him as Chief Executive Officer and President of Phibro Animal Health Corporation.
As part of the transition, Jack Bendheim will continue to serve as Chairman of the Company’s Board of Directors, ensuring continuity in governance and strategic oversight. The Company emphasized that the transition reflects Phibro’s disciplined succession planning process and long-standing commitment to leadership continuity, cultural alignment, and sustainable growth.
A Strategic Transition for the Next Phase of Growth
Phibro’s Board of Directors unanimously endorsed the leadership transition, expressing strong confidence in the Company’s executive leadership team and its ability to execute Phibro’s growth strategy in an increasingly complex global animal health landscape. The full executive leadership team will remain in place, reinforcing stability and operational momentum during the transition period.
The Company noted that the leadership change comes at a time of strength for Phibro, following years of global expansion, portfolio diversification, and operational transformation. With a solid foundation in animal health, nutrition, and performance products, Phibro is well positioned to continue addressing the evolving needs of livestock producers and customers worldwide.
Jack Bendheim’s Enduring Legacy at Phibro
Jack Bendheim’s career at Phibro spans more than five decades, underscoring his profound impact on the Company’s evolution and global standing. He joined Phibro in 1969 and steadily advanced through a variety of management and executive roles, gaining deep operational insight and industry expertise along the way. He was appointed President in 1988 and later named Chief Executive Officer in March 2014.
Throughout his tenure, Jack Bendheim guided Phibro through periods of significant growth and change, transforming the Company into a globally recognized leader in animal health and nutrition. Under his leadership, Phibro expanded its geographic footprint, strengthened its product portfolio, and enhanced its operational capabilities to better serve customers across diverse markets.
During this period, the Company also navigated shifting regulatory environments, changing customer demands, and evolving global supply chains—challenges that required disciplined leadership and a long-term strategic perspective. Jack Bendheim’s steady guidance helped Phibro maintain its reputation as a trusted partner to livestock producers while reinforcing its commitment to innovation, quality, and animal well-being.
As Phibro continues to evolve and expand, this is the right moment to transition leadership to guide the Company’s next chapter,” said Jack Bendheim. “Dani brings deep knowledge of our business, strong operational discipline, and a global perspective that aligns with the future of our industry. I have full confidence in his ability to lead Phibro forward while maintaining the values, relationships, and commitment to animal health that have defined our Company for decades.”
The Role of Executive Chairman
In his new role as Executive Chairman, Jack Bendheim will remain actively engaged in the Company’s strategic direction. He will provide oversight on long-term growth initiatives, support key customer and industry relationships, and work closely with the executive leadership team and Board of Directors. This role is designed to leverage his extensive institutional knowledge and industry experience while enabling the next generation of leadership to manage day-to-day operations.
The Company highlighted that the Executive Chairman position reflects Phibro’s thoughtful approach to leadership transitions—ensuring continuity while empowering new leadership to drive innovation and performance.
Dani Bendheim: A Proven Leader with Deep Company Experience
Dani Bendheim brings nearly three decades of experience within Phibro, having joined the Company in 1997. Over the years, he has held a series of increasingly senior leadership roles that have provided him with broad exposure across Phibro’s global operations and strategic functions.
He was appointed Vice President of Business Development in 2001, where he played a key role in expanding the Company’s portfolio and identifying new growth opportunities. In 2004, he became President of Performance Products, leading one of Phibro’s core business segments and strengthening its market position. In March 2014, Dani Bendheim was named Executive Vice President, Corporate Strategy, further deepening his involvement in shaping the Company’s long-term direction.
Most recently, he served as Chief Transformation Officer, leading the Company’s Phibro Forward initiative—an enterprise-wide transformation program focused on driving operational efficiency, accelerating growth, and strengthening organizational culture. The initiative has been instrumental in enhancing cross-functional collaboration, streamlining processes, and positioning Phibro for sustained success in a competitive global environment.
With extensive experience across business development, strategy, operations, and transformation, Dani Bendheim brings a well-rounded leadership profile to his new role as Chief Executive Officer and President.
Commitment to Continuity and Innovation
Phibro emphasized that Dani Bendheim’s appointment reflects the Company’s long-standing commitment to disciplined succession planning and leadership development from within. His deep understanding of Phibro’s business model, customer relationships, and global footprint is expected to support a seamless transition and continued execution of the Company’s strategic priorities.
I am honored to take on this role and grateful for my father’s decades of leadership and guidance,” said Dani Bendheim. “Phibro is in the best position it has ever been—a customer-focused company with a strong foundation and a commitment to innovation. I look forward to continuing to work with our global leadership team and our dedicated employees worldwide to advance our strategy, support our customers, and build on the Company’s momentum.”
Looking Ahead
As Phibro Animal Health Corporation looks to the future, the Company remains focused on delivering high-quality solutions that support animal health, nutrition, and productivity while meeting the evolving needs of customers around the world. The planned leadership transition is intended to reinforce this mission by combining continuity, experience, and forward-looking leadership.
With Jack Bendheim continuing to provide strategic oversight as Executive Chairman and Dani Bendheim assuming operational leadership as Chief Executive Officer and President, Phibro is positioned to enter its next phase of growth with confidence, stability, and a clear strategic vision.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals
This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts.the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
